TECH insider trading
NasdaqGS HealthcareBIO-TECHNE Corp — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About BIO-TECHNE Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Company website: www.bio-techne.com
TECH insider activity at a glance
FilingIQ has scored 774 insider transactions for TECH since Jun 8, 2015. The most recent filing in our index is dated May 8, 2026.
Across the full history, 4 open-market purchases
and 269 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TECH insider trades is 62.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TECH Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for TECH?
- FilingIQ tracks 774 Form 4 insider transactions for TECH (BIO-TECHNE Corp), covering filings from Jun 8, 2015 onwards. 31 of those were filed in the last 90 days.
- Are TECH insiders net buyers or net sellers?
- Across the full Form 4 history for TECH, 4 transactions (1%) were open-market purchases and 269 (35%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TECH insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is TECH in?
- BIO-TECHNE Corp (TECH) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.68B.
Methodology & sources
Every TECH insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.